- Home
- BIIB vs IOT Comparison
BIIB vs IOT Comparison
Compare BIIB & IOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- IOT
- Stock Information
- Founded
- BIIB 1978
- IOT 2015
- Country
- BIIB United States
- IOT United States
- Employees
- BIIB N/A
- IOT N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- IOT Retail: Computer Software & Peripheral Equipment
- Sector
- BIIB Health Care
- IOT Technology
- Exchange
- BIIB Nasdaq
- IOT Nasdaq
- Market Cap
- BIIB 19.9B
- IOT 20.8B
- IPO Year
- BIIB 1991
- IOT 2021
- Fundamental
- Price
- BIIB $131.32
- IOT $37.98
- Analyst Decision
- BIIB Buy
- IOT Buy
- Analyst Count
- BIIB 27
- IOT 14
- Target Price
- BIIB $220.50
- IOT $49.07
- AVG Volume (30 Days)
- BIIB 1.7M
- IOT 5.5M
- Earning Date
- BIIB 04-23-2025
- IOT 03-06-2025
- Dividend Yield
- BIIB N/A
- IOT N/A
- EPS Growth
- BIIB 40.28
- IOT N/A
- EPS
- BIIB 11.18
- IOT N/A
- Revenue
- BIIB $9,675,900,000.00
- IOT $1,249,199,000.00
- Revenue This Year
- BIIB N/A
- IOT $23.92
- Revenue Next Year
- BIIB N/A
- IOT $22.80
- P/E Ratio
- BIIB $11.75
- IOT N/A
- Revenue Growth
- BIIB N/A
- IOT 33.26
- 52 Week Low
- BIIB $128.51
- IOT $27.14
- 52 Week High
- BIIB $238.00
- IOT $61.90
- Technical
- Relative Strength Index (RSI)
- BIIB 32.77
- IOT 37.83
- Support Level
- BIIB $138.65
- IOT $36.55
- Resistance Level
- BIIB $144.07
- IOT $38.82
- Average True Range (ATR)
- BIIB 3.61
- IOT 1.54
- MACD
- BIIB -1.09
- IOT 0.27
- Stochastic Oscillator
- BIIB 14.92
- IOT 21.31
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About IOT Samsara Inc.
Samsara Inc provides an end-to-end solution for operations: The solution connects physical operations data to the Connected Operations Cloud, which consists of the Data Platform and Application. Geographically, it derives a majority of its revenue from the United States.